Manufacturing (industry group 28), latest filing in August 2026

Adma Biologics Inc

Adma Biologics Inc has 6 Schedule 13D or 13G filings on record since 2025-07-29. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Adma Biologics Inc by CUSIP 000899104 and gives its principal executive office as 465 ROUTE 17 SOUTH, RAMSEY, NJ 07446 (SCHEDULE 13G, 2026-08-07).

Swipe the table sideways to see every column.

Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Aldeyra Therapeutics, Inc. by CUSIP 01438T106 and gives its principal executive office as 131 HARTWELL AVENUE, SUITE 320, LEXINGTON, MA 02421 (SCHEDULE 13G, 2026-08-12).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Amarin Corporation PLC

Amarin Corporation PLC has 1 Schedule 13D or 13G filing on record since 2026-08-27. 1 holder's latest filing reports 5% or more of ordinary shares, par value 50 pence per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Amarin Corporation PLC by CUSIP 023111206 and gives its principal executive office as One Central Plaza, 5th Floor, 36 Dame Street, Dublin 2 (SCHEDULE 13D/A, 2026-08-27).

Swipe the table sideways to see every column.

Apnimed, Inc.

Apnimed, Inc. has 2 Schedule 13D or 13G filings on record since 2026-08-06. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Apnimed, Inc. by CUSIP 03770Y107 and gives its principal executive office as 39 John F. Kennedy Street, 4th Floor, Cambridge, MA 02138 (SCHEDULE 13G, 2026-08-07).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Argenx Se - Adr

Argenx Se - Adr has 5 Schedule 13D or 13G filings on record since 2025-08-12. 1 holder's latest filing reports 5% or more of adr. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Argenx Se - Adr by CUSIP 04016X101 and gives its principal executive office as INDUSTRIEPARK ZWIJNAARDE 7, BUILDING C B-9052, ZWIJNAARDE (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc. has 4 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Aridis Pharmaceuticals, Inc. by CUSIP 040334104 and gives its principal executive office as 983 University Avenue, Bldg. B, Los Gatos, CA 95032 (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

Aspire Biopharma Holdings, Inc.

Aspire Biopharma Holdings, Inc. has 7 Schedule 13D or 13G filings on record since 2026-02-12. 3 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Aspire Biopharma Holdings, Inc. by CUSIP 738920305 and gives its principal executive office as 23150 FASHION DRIVE, SUITE 232, ESTERO, FL 33928 (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2026-04-08. 3 holders' latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Atrium Therapeutics, Inc. by CUSIP 04965N104 and gives its principal executive office as 3020 CALLAN ROAD, SAN DIEGO, CA 92121 (SCHEDULE 13G, 2026-08-14).

Swipe the table sideways to see every column.

Aytu Biopharma, Inc

Aytu Biopharma, Inc has 7 Schedule 13D or 13G filings on record since 2025-08-13. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Aytu Biopharma, Inc by CUSIP 054754858 and gives its principal executive office as 7900 E. UNION AVENUE, SUITE 920, DENVER, CO 80237 (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

Bio-Techne Corp

Bio-Techne Corp has 7 Schedule 13D or 13G filings on record since 2025-07-16. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Bio-Techne Corp by CUSIP 09073M104 and gives its principal executive office as 614 McKinley Place N.E., SUITE 1500, Minneapolis, MN 55413 (SCHEDULE 13G/A, 2026-08-06).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Biodexa Pharmaceuticals Plc

Biodexa Pharmaceuticals Plc has 5 Schedule 13D or 13G filings on record since 2025-11-14. 2 holders' latest filing reports 5% or more of american depositary shares, each representing four hundred ordinary shares. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Biodexa Pharmaceuticals Plc by CUSIP 59564R872 and gives its principal executive office as 1 Caspian Point Caspian Way, Cardiff (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

Biogen Inc

Biogen Inc has 8 Schedule 13D or 13G filings on record since 2025-11-10. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Biogen Inc by CUSIP 09062X103 and gives its principal executive office as 225 BINNEY STREET, Cambridge, MA 02142 (SCHEDULE 13G/A, 2026-08-06).

Swipe the table sideways to see every column.

Bristol-Myers Squibb Co

Bristol-Myers Squibb Co has 4 Schedule 13D or 13G filings on record since 2025-10-31. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Bristol-Myers Squibb Co by CUSIP 110122108 and gives its principal executive office as ROUTE 206 & PROVINCE LINE ROAD, PRINCETON, NJ 08540 (SCHEDULE 13G, 2026-08-07).

Swipe the table sideways to see every column.

Cabot Corporation

Cabot Corporation has 5 Schedule 13D or 13G filings on record since 2026-03-26. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Cabot Corporation by CUSIP 127055101 and gives its principal executive office as Two Seaport Lane, Suite 1400, Boston, MA 02210 (SCHEDULE 13G, 2026-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics, Inc. has 1 Schedule 13D or 13G filing on record since 2026-08-07. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Cadrenal Therapeutics, Inc. by CUSIP 127636207 and gives its principal executive office as 822 A1A North, Suite 306, Ponte Vedra, FL 32082 (SCHEDULE 13G, 2026-08-07).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Celanese Corp

Celanese Corp has 8 Schedule 13D or 13G filings on record since 2025-07-28. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: 1 filing or notice, latest 2025-10-28 (layoff filings and notices).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Celanese Corp by CUSIP 150870103 and gives its principal executive office as 222 W. Las Colinas Blvd., Suite 900N, Irving, TX 75039 (SCHEDULE 13G/A, 2026-08-12).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Cf Industries Holdings Inc

Cf Industries Holdings Inc has 6 Schedule 13D or 13G filings on record since 2025-08-06. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Cf Industries Holdings Inc by CUSIP 125269100 and gives its principal executive office as 2375 WATERVIEW DRIVE, NORTHBROOK, IL 60062 (SCHEDULE 13G, 2026-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Citius Oncology, Inc.

Citius Oncology, Inc. has 8 Schedule 13D or 13G filings on record since 2025-07-25. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Citius Oncology, Inc. by CUSIP 17331Y109 and gives its principal executive office as 11 COMMERCE DRIVE, 1ST FLOOR, CRANFORD, NJ 07016 (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. has 3 Schedule 13D or 13G filings on record since 2025-10-27. 1 holder's latest filing reports 5% or more of common stock, $0.001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Citius Pharmaceuticals, Inc. by CUSIP 17322U306 and gives its principal executive office as 11 Commerce Drive, 1st Floor, Cranford, NJ 07016 (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

CNBX Pharmaceuticals Inc.

CNBX Pharmaceuticals Inc. has 5 Schedule 13D or 13G filings on record since 2025-08-13. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies CNBX Pharmaceuticals Inc. by CUSIP 13764M209 and gives its principal executive office as #3 Bethesda Metro Center, Suite 700, Bethesda, MD 20814 (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. has 7 Schedule 13D or 13G filings on record since 2025-08-14. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies CNS Pharmaceuticals, Inc. by CUSIP 18978H508 and gives its principal executive office as 2100 West Loop South, Suite 900, Houston, TX 77027 (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Decoy Therapeutics Inc.

Decoy Therapeutics Inc. has 5 Schedule 13D or 13G filings on record since 2025-10-14. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Decoy Therapeutics Inc. by CUSIP 79400X602 and gives its principal executive office as 2450 Holcombe Blvd., Suite X, Houston, TX 77021 (SCHEDULE 13G, 2026-08-14).

Swipe the table sideways to see every column.

Denali Therapeutics Inc.

Denali Therapeutics Inc. has 7 Schedule 13D or 13G filings on record since 2025-08-12. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Denali Therapeutics Inc. by CUSIP 24823R105 and gives its principal executive office as 161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA 94080 (SCHEDULE 13G/A, 2026-08-04).

Swipe the table sideways to see every column.

Dow Inc

Dow Inc has 3 Schedule 13D or 13G filings on record since 2026-03-26. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: about 4,500 jobs, latest 2026-01-29 (layoff filings and notices).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Dow Inc by CUSIP 260557103 and gives its principal executive office as 2211 H H DOW WAY, MIDLAND, MI 48642 (SCHEDULE 13G, 2026-08-07).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Dupont De Nemours Inc

Dupont De Nemours Inc has 3 Schedule 13D or 13G filings on record since 2026-03-26. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Dupont De Nemours Inc by CUSIP 26614N201 and gives its principal executive office as 974 CENTRE ROAD BUILDING 730, WILMINGTON, DE 19805 (SCHEDULE 13G, 2026-08-07).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Element Solutions Inc

Element Solutions Inc has 5 Schedule 13D or 13G filings on record since 2026-03-23. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Element Solutions Inc by CUSIP 28618M106 and gives its principal executive office as 500 S POINTE DRIVE, SUITE 200, MIAMI BEACH (SCHEDULE 13G, 2026-08-13).

Martin E. Franklin

Item 4 of the Statement is hereby amended by the addition of the following: On March 23, 2026, the Proxy Agreement dated February 27, 2020 was terminated, effective immediately (the "Termination"). Pursuant to the Proxy Agreement, Franklin had the power to vote the Tasburgh shares of Common Stock during the proxy term. As a result of the termination of the Proxy Agreement, Franklin no longer has beneficial ownership of the shares of Common Stock owned by Tasburgh. In 2022, the Proxy Agreement given by Powder Horn Hill Partners II, LLC terminated by its terms, and as such, the Lillie Reporting Persons ceased to be Reporting Persons.Item 4 of the SCHEDULE 13D/A filed 2026-03-23

Swipe the table sideways to see every column.

e.l.f. Beauty, Inc.

e.l.f. Beauty, Inc. has 4 Schedule 13D or 13G filings on record since 2025-11-13. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies e.l.f. Beauty, Inc. by CUSIP 26856L103 and gives its principal executive office as 601 12TH STREET, OAKLAND, CA 1400 (SCHEDULE 13G/A, 2026-08-04).

Swipe the table sideways to see every column.

Emergent BioSolutions Inc.

Emergent BioSolutions Inc. has 9 Schedule 13D or 13G filings on record since 2025-07-17. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: about 93 jobs, latest 2026-08-05 (layoff filings and notices).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Emergent BioSolutions Inc. by CUSIP 29089Q105 and gives its principal executive office as 300 Professional Dr, Gaithersburg, MD 20879 (SCHEDULE 13G, 2026-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Enlivex Ltd.

Enlivex Ltd. has 2 Schedule 13D or 13G filings on record since 2025-08-14. 1 holder's latest filing reports 5% or more of ordinary shares, par value nis 6.00 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Enlivex Ltd. by CUSIP M4130Y171 and gives its principal executive office as 14 Einstein Street, Nes Ziona (SCHEDULE 13G, 2026-08-13).

Swipe the table sideways to see every column.

Fitlife Brands, Inc.

Fitlife Brands, Inc. has 1 Schedule 13D or 13G filing on record since 2026-08-07. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Fitlife Brands, Inc. by CUSIP 33817P405 and gives its principal executive office as 5214 S. 136TH STREET, OMAHA, NE 68137 (SCHEDULE 13G/A, 2026-08-07).

The percentage calculated in Item 11 is based on 9,391,072 shares of Common Stock outstanding as of May 13, 2026, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and as filed with the SEC on May 14, 2026.Askeladden Capital Management LLC, SCHEDULE 13G/A, 2026-08-07

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Galectin Therapeutics Inc

Galectin Therapeutics Inc has 1 Schedule 13D or 13G filing on record since 2026-08-04. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Galectin Therapeutics Inc by CUSIP 363225202 and gives its principal executive office as 4960 PEACHTREE INDUSTRIAL BOULEVARD, SUITE 240, NORCROSS, GA 30071 (SCHEDULE 13D/A, 2026-08-04).

Richard E. Uihlein

The Shares were acquired for investment purposes and were not acquired with the purpose or effect of changing or influencing control of the Company.Item 4 of the SCHEDULE 13D/A filed 2026-08-04

Swipe the table sideways to see every column.

Gevo Inc

Gevo Inc has 3 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Gevo Inc by CUSIP 374396406 and gives its principal executive office as 345 INVERNESS DRIVE SOUTH BUILDING C, SUITE 310, ENGLEWOOD, CO 80112 (SCHEDULE 13G, 2026-08-07).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Glass House Brands Inc.

Glass House Brands Inc. has 1 Schedule 13D or 13G filing on record since 2026-08-14. 1 holder's latest filing reports 5% or more of subordinate, restricted and limited voting shares, without par value. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Glass House Brands Inc. by CUSIP 377130406 and gives its principal executive office as 3645 Long Beach Blvd., Long Beach, CA 90807 (SCHEDULE 13G, 2026-08-14).

Swipe the table sideways to see every column.

Green Plains Inc

Green Plains Inc has 13 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Green Plains Inc by CUSIP 393222104 and gives its principal executive office as 1811 AKSARBEN DRIVE, OMAHA, NE 68106 (SCHEDULE 13G/A, 2026-11-03).

Swipe the table sideways to see every column.

GSK plc

GSK plc has 2 Schedule 13D or 13G filings on record since 2026-05-06. 1 holder's latest filing reports 5% or more of ordinary shares and american depositary shares. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies GSK plc by CUSIP 37733W204 and gives its principal executive office as 79 New Oxford Street, London (SCHEDULE 13G/A, 2026-08-13).

Swipe the table sideways to see every column.

Hexcel Corp

Hexcel Corp has 11 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Hexcel Corp by CUSIP 428291108 and gives its principal executive office as TWO STAMFORD PLAZA, 281 TRESSER BLVD., 16TH FLOOR, STAMFORD, CT 06901 (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

ImmunityBio, Inc.

ImmunityBio, Inc. has 3 Schedule 13D or 13G filings on record since 2025-11-10. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies ImmunityBio, Inc. by CUSIP 45256X103 and gives its principal executive office as 3530 John Hopkins Court, San Diego, CA 92121 (SCHEDULE 13D/A, 2026-08-06).

Swipe the table sideways to see every column.

Immunome Inc

Immunome Inc has 14 Schedule 13D or 13G filings on record since 2025-07-29. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Immunome Inc by CUSIP 45257U108 and gives its principal executive office as 18702 North Creek Parkway, Suite 100, Bothell, WA 98011 (SCHEDULE 13G, 2026-10-30).

Swipe the table sideways to see every column.

Incannex Healthcare Inc.

Incannex Healthcare Inc. has 1 Schedule 13D or 13G filing on record since 2026-08-14. 1 holder's latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Incannex Healthcare Inc. by CUSIP 45333F208 and gives its principal executive office as 8 Century Circuit, Suite 105, Norwest (SCHEDULE 13G, 2026-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

INSMED Inc

INSMED Inc has 14 Schedule 13D or 13G filings on record since 2025-07-17. 3 holders' latest filing reports 5% or more of common stock, par value $0.01 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies INSMED Inc by CUSIP 457669307 and gives its principal executive office as 700 US HIGHWAY 202/206, BRIDGEWATER, NJ 08807 (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Intellia Therapeutics Inc

Intellia Therapeutics Inc has 12 Schedule 13D or 13G filings on record since 2025-11-04. 4 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Intellia Therapeutics Inc by CUSIP 45826J105 and gives its principal executive office as 40 ERIE STREET SUITE 130, CAMBRIDGE, MA 02139 (SCHEDULE 13G, 2026-08-07).

Swipe the table sideways to see every column.

Iovance Biotherapeutics Inc

Iovance Biotherapeutics Inc has 7 Schedule 13D or 13G filings on record since 2025-07-17. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Iovance Biotherapeutics Inc by CUSIP 462260100 and gives its principal executive office as 999 SKYWAY ROAD SUITE 150, SAN CARLOS, CA 94070 (SCHEDULE 13G, 2026-08-07).

Swipe the table sideways to see every column.

Jazz Pharmaceuticals Plc

Jazz Pharmaceuticals Plc has 3 Schedule 13D or 13G filings on record since 2026-03-27. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Jazz Pharmaceuticals Plc by CUSIP G50871105 and gives its principal executive office as FIFTH FLOOR, WATERLOO EXCHANGE, WATERLOO ROAD, DUBLIN (SCHEDULE 13G, 2026-08-06).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Kamada Ltd

Kamada Ltd has 2 Schedule 13D or 13G filings on record since 2026-03-16. 1 holder's latest filing reports 5% or more of ordinary shares, par value nis 1.00 each. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Kamada Ltd by CUSIP M6240T109 and gives its principal executive office as 2 Holtzman St., Science Park, P.O. Box 4081, Rehovot (SCHEDULE 13G/A, 2026-08-20).

Gov Financial Holdings Ltd. 2.52%* Insight Capital Ltd. 2.33%* Leon Recanati 6.04%* * Calculated based on 57,686,056 Ordinary Shares of the Issuer outstanding as of December 31, 2025.Recanati Leon, SCHEDULE 13G/A, 2026-03-16

Swipe the table sideways to see every column.

Kenvue Inc

Kenvue Inc has 10 Schedule 13D or 13G filings on record since 2025-07-29. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: about 69 jobs, latest 2026-02-17 (layoff filings and notices).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Kenvue Inc by CUSIP 49177J102 and gives its principal executive office as 1 KENVUE WAY, SUMMIT, NJ 07901 (SCHEDULE 13G/A, 2026-08-06).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Kyntra Bio, Inc.

Kyntra Bio, Inc. has 6 Schedule 13D or 13G filings on record since 2025-07-29. 1 holder's latest filing reports 5% or more of common stock, $0.01 par value. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Kyntra Bio, Inc. by CUSIP 31572Q881 and gives its principal executive office as 350 Bay Street, Suite 100 #6009, San Francisco, CA 94133 (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Lakewood-Amedex Biotherapeutics Inc.

Lakewood-Amedex Biotherapeutics Inc. has 3 Schedule 13D or 13G filings on record since 2026-06-23. 3 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Lakewood-Amedex Biotherapeutics Inc. by CUSIP 51255A201 and gives its principal executive office as 8031 Cooper Creek Blvd., Unit 103, University Park, FL 34201 (SCHEDULE 13G, 2026-08-14).

24.04% (1) (1) The beneficial ownership percentage is calculated based on 14,290,892 shares of the Issuer issued and outstanding as of March 31, 2026.HPW Investments Holding Ltd., SCHEDULE 13G, 2026-06-23

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Legend Biotech Corp

Legend Biotech Corp has 4 Schedule 13D or 13G filings on record since 2025-08-06. 1 holder's latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Legend Biotech Corp by CUSIP 52490G102 and gives its principal executive office as 2101 COTTONTAIL LANE, SOMERSET, NJ 08873 (SCHEDULE 13G/A, 2026-08-06).

Swipe the table sideways to see every column.

Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Inc has 7 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Ligand Pharmaceuticals Inc by CUSIP 53220K504 and gives its principal executive office as 3911 Sorrento Valley Blvd, Suite 110, San Diego (SCHEDULE 13G, 2026-08-13).

Swipe the table sideways to see every column.

Lightbridge Corp

Lightbridge Corp has 9 Schedule 13D or 13G filings on record since 2025-07-18. 2 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Lightbridge Corp by CUSIP 53224K302 and gives its principal executive office as 11710 PLAZA AMERICA DRIVE SUITE 2000, RESTON, VA 20190 (SCHEDULE 13G, 2026-08-07).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Lipocine Inc.

Lipocine Inc. has 5 Schedule 13D or 13G filings on record since 2025-12-23. 2 holders' latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Lipocine Inc. by CUSIP 53630X203 and gives its principal executive office as 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT 84108 (SCHEDULE 13G/A, 2026-08-14).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Lisata Therapeutics, Inc.

Lisata Therapeutics, Inc. has 1 Schedule 13D or 13G filing on record since 2026-08-26. 1 holder's latest filing reports 5% or more of common stock, par value $0.001 per share. Each figure below is the holder's own, as filed, with the filing linked.

Layoffs on record: 1 filing or notice, latest 2026-08-04 (layoff filings and notices).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

The latest filing identifies Lisata Therapeutics, Inc. by CUSIP 128058302 and gives its principal executive office as 110 ALLEN ROAD, SECOND FLOOR, BASKING RIDGE, NJ 07920 (SCHEDULE 13G, 2026-08-26).

Swipe the table sideways to see every column.

Swipe the table sideways to see every column.

Lyondellbasell Industries N.V.